Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2007

01.01.2007 | Original article

Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma

verfasst von: Yoshihiro Nishiyama, Yuka Yamamoto, Toshihide Monden, Yasuhiro Sasakawa, Nobuyuki Kawai, Katashi Satoh, Motoomi Ohkawa

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to investigate the accumulation of FDG in immunocompetent patients with primary central nervous system (CNS) lymphoma using qualitative and quantitative PET images and to compare baseline with follow-up PET after therapy.

Methods

Twelve immunocompetent patients with CNS lymphoma were examined. Dynamic emission data were acquired for 60 min immediately following injection of FDG. In seven patients, repeated PET studies were performed after treatment. Applying a three-compartment five-parameter model, K 1, k 2, k 3, k 4, vascular fraction (V B ) and cerebral metabolic rate of glucose (CMRGlc) were obtained. We evaluated the FDG uptake visually using qualitative and parametric images and quantitatively using parametric images.

Results

A total of 12 lesions were identified in ten patients with newly diagnosed CNS lymphoma. On visual analysis, ten lesions showed an increase on qualitative images, eight showed an increase on K 1 images, 12 showed an increase on k 3 images and ten showed an increase on CMRGlc images. On quantitative analysis, k 2, k 3 and CMRGlc values of the lesion were significantly different from those of the normal grey matter (p<0.02–0.0005). A total of three lesions were identified in two patients with recurrent tumour. All three lesions showed an increase on qualitative, k 3 and CMRGlc images. The K 1, k 2, k 3 and CMRGlc values after treatment were significantly different from those obtained before treatment (p<0.04–0.008).

Conclusion

Kinetic analysis, especially with respect to k 3, using dynamic FDG PET might be helpful for diagnosis of CNS lymphoma and for monitoring therapeutic assessment.
Literatur
1.
Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988;68:835–854PubMedCrossRef
2.
Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003;361:323–331PubMedCrossRef
3.
Jiddane M, Nicoli F, Diaz P, Bergvall U, Vincentelli F, Hassoun J, et al. Intracranial malignant lymphoma: report of 30 cases and review of the literature. J Neurosurg 1986;65:592–599PubMed
4.
Basso U, Brandes AA. Diagnostic advances and new trends for treatment of primary central nervous system lymphoma. Eur J Cancer 2002;38:1298–1312PubMedCrossRef
5.
Coleman RE. Clinical PET in oncology. Clin Pos Imaging 1998;1:15–30CrossRef
6.
Newman J, Francis I, Kaminski M, Wahl RL. FDG-PET imaging in lymphoma: correlation with CT. Radiology 1994;190:111–116PubMed
7.
Alavi JB, Alavi A, Chawluk J, Wahl RL. PET in patients with glioma. A predictor of prognosis. Cancer 1988;62:1074–1078PubMedCrossRef
8.
Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med 1998;25:1261–1269PubMedCrossRef
9.
Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992;33:532–536PubMed
10.
Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993;34:567–575PubMed
11.
Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371–388PubMedCrossRef
12.
Huang SC, Williams BA, Barrio JR, Krivokapich J, Nissenson C, Hoffman EJ, et al. Measurement of glucose and 2-deoxy-2 [18F] fluoro-D-glucose transport and phosphorylation rates in myocardium using dual-tracer kinetic experiment. FEBS Lett 1987;216:128–132PubMedCrossRef
13.
Mankoff D, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500–509PubMed
14.
Wu HM, Bergsneider M, Glenn TC, Yeh E, Hovda DA, Phelps ME, et al. Measurement of the global lumped constant for 2-deoxy-2-[18F] fluoro-D-glucose in normal human brain using [15O] water and 2-deoxy-2 [18F] fluoro-D-glucose positron emission tomography imaging: a method with validation based on multiple methodologies. Mol Imaging Biol 2003;5:32–41PubMedCrossRef
15.
Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 2002;29:443–453PubMedCrossRef
16.
Ishikawa M, Kikuchi H, Nagata I. Glucose consumption and rate constants for 18F-fluorodeoxyglucose in human gliomas. Neurol Med Chir 1990;30:377–381CrossRef
17.
Herholz K, Rudolf J, Heiss WD. FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurooncol 1992;12:159–165PubMedCrossRef
18.
Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Bernd L, Haberkorn U, Ewerbeck V, et al. 18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med 2004;45:1528–1535PubMed
19.
Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IG, Matthies A, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006;33:164–168PubMedCrossRef
20.
O’Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997;38:1575–1583PubMed
21.
Mineura K, Sasajima T, Kowada M, Ogawa T, Hatazawa J, Shishido F, et al. Perfusion and metabolism in predicting the survival of patients with gliomas. Cancer 1994;73:2386–2394PubMedCrossRef
22.
Terae S, Ogata A. Nonenhancing primary central nervous system lymphoma. Neuroradiology 1996;38:34–37PubMedCrossRef
23.
Earnest F 4th, Kelly PJ, Scheithauer BW, Kall BA, Cascino TL, Ehman RL, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988;166:823–827PubMed
24.
Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, et al. Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323–1329PubMed
25.
Wahl RL, Zasadny KR, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101–2111PubMed
26.
Romer W, Hanauske AR, Ziegler S, Thodtmann R, Weber W, Fuchs C, et al. Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464–4471PubMed
27.
Hautzel H, Muller-Gartner HW. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 1997;38:1384–1386PubMed
28.
Fischman AJ, Thornton AF, Frosch MP, Swearinger B, Gonzalez RG, Alpert NM. FDG hypermetabolism associated with inflammatory necrotic changes following radiation of meningioma. J Nucl Med 1997;38:1027–1029PubMed
29.
Haberkorn U, Strauss LG, Dimitrakopoupou A, Engenhart R, Oberdorfer F, Ostertag H, et al. PET studies of dluorodeoxy glucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485–1490PubMed
30.
Gjedde A, Wienhard K, Heiss WD, Kloster G, Diemer NH, Herholz K, et al. Comparative regional analysis of 2-fluoro deoxyglucose and methyl glucose uptake in brain of four stroke patients with special reference to the regional estimation of the lumped constant. J Cereb Blood Flow Metab 1985;5:163–178PubMed
31.
Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, et al. The [11C]-deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897–916PubMedCrossRef
32.
Ogawa T, Kanno I, Hatazawa J, Inugami A, Fujita H, Shimosegawa E, et al. Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. RadioGraphics 1994;14:101–110PubMed
33.
Pruim J, Willemsen ATM, Molenaar W, van Waarde A, Paans AM, Heesters MA, et al. Brain tumors: l-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology 1995;197:221–226PubMed
Metadaten
Titel
Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma
verfasst von
Yoshihiro Nishiyama
Yuka Yamamoto
Toshihide Monden
Yasuhiro Sasakawa
Nobuyuki Kawai
Katashi Satoh
Motoomi Ohkawa
Publikationsdatum
01.01.2007
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-006-0153-z

Weitere Artikel der Ausgabe 1/2007

European Journal of Nuclear Medicine and Molecular Imaging 1/2007 Zur Ausgabe

Original article

Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA

Original article

Bone involvement in patients with lymphoma: the role of FDG-PET/CT

Focus on....

Imaging atherosclerosis in the vulnerable patient

Original article

Sixty-four slice spiral CT angiography does not predict the functional relevance of coronary artery stenoses in patients with stable angina

Original article

Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer

Original article

Use of coronary calcium score scans from stand-alone multislice computed tomography for attenuation correction of myocardial perfusion SPECT